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To quickly control infectious disease outbreaks, extensive 
information is required to identify the source and transmission 
routes, and to evaluate the effect of containment policies. 
Traditionally, scientists have used travel- and contact-tracing 
methods, but the recent SARS epidemic showed that sequence-
based techniques for pathogen detection can also be important 
tools to help understand outbreaks. Jianjun Liu and colleagues 
adapted mass spectrometry (MS)–based genotyping, already 
used as a high-throughput way of detecting single nucleotide 
polymorphisms in human DNA, to the analysis of the SARS virus 
from clinical samples. 
The major breakthroughs against SARS were the discovery 
of the SARS coronavirus (SARS-CoV) as the etiological agent 
and the sequencing of the SARS genome. Liu’s colleagues at 
the Genome Institute of Singapore had previously shown that 
common genetic variants in the SARS-CoV genome could 
be used as molecular ﬁ  ngerprints to help trace the route of 
infection. However, as “sequence analysis of large numbers of 
clinical samples is challenging, cumbersome, and expensive,” 
they felt that “what is needed is a rapid, sensitive, high 
throughput, and cost-effective screening method.” Towards this 
goal, Liu and colleagues now demonstrate that an MS-based 
technique can quickly yield accurate information on clinical 
isolates (in this case from the 2003 SARS outbreak in Singapore). 
The scientists demonstrate the sensitivity of the assay in 
detecting SARS-CoV variations and test it further in cultured viral 
Mass Spectometry–Based SARS Genotyping
DOI: 10.1371/journal.pmed.0020052
Of the 40 million people worldwide 
with HIV, 30 million live in the developing 
world. By far the worst hit region is sub-
Saharan Africa, where nearly four million 
children have lost one or both parents to 
HIV/AIDS since 2000. Is heterosexual 
transmission the driving force 
behind the HIV epidemic in sub-
Saharan Africa? In a controversial 
debate, some researchers have 
suggested that other factors such as 
unsafe medical injection practices 
may also be to blame, and that by 
overlooking, and even suppressing, 
analysis of this possible route of 
transmission, the current focus on 
preventing sexual transmission 
may be misguided. In this month’s 
PLoS Medicine, Ben Lopman and 
colleagues argue that although it is 
right to criticize the lack of evidence 
on unsafe medical injection, ﬁ  eld 
data are hard to collect. They note 
that in the only published study 
addressing this issue, Kiwanuka and 
colleagues found no link between 
unsafe injections and HIV spread in 
rural Uganda. In an effort to “inform 
the debate” further, Lopman and 
colleagues looked at the association 
between HIV and unsafe injection 
practices in rural Zimbabwe.
The team analyzed data from 
adults in Manicaland, a rural part of 
Zimbabwe, who were taking part in the 
Manicaland HIV/STD Prevention Study. 
In 1999 and 2000, eligible patients were 
tested for HIV and surveyed (86.7% were 
HIV negative at the start of the study), 
and were followed up three years later. 
The team collected survey data on 
injections in the patients, who were male 
and female adults aged 15 to 54 years old, 
and tested for an association between 
injection exposure and HIV infection. 
In 2002 and 2003, 505 of the men and 
1,342 of the women, representing a 
69.7% follow-up, were again interviewed 
and tested for HIV infection. Of these, 
40% reported having had an injection 
or needle prick during the study period. 
A total of 67 patients developed HIV 
during the study; of these 13 (19%) said 
they had not had sex during the study 
period and 40 (60%) said they had not 
had an injection. The statistical analysis 
found no signiﬁ  cant association between 
injections and HIV infection in 
men or women. 
Patients who had HIV when 
the study began did not have 
higher rates of injections. Instead, 
injections were highly associated 
with childbirth and pregnancy. But 
since HIV–positive women have 
reduced fertility, a reduction in 
the use of maternal services may 
partially explain why injections 
were not more common in these 
HIV-positive patients. In this 
study, the strongest predictor of 
HIV infection was symptoms of 
sexually transmitted disease. 
Despite problems of recall bias 
and under-reporting of sexual 
activity—a particularly difﬁ  cult 
problem in studies in Africa—
sexual behavior is consistently 
linked with HIV incidence. Where 
does this leave the debate over 
injections in Africa? Certainly, 
for this community, they do not 
seem to be a major source of 
HIV infection, and local policy-
makers would therefore do best to 
concentrate on the prevention of sexually 
transmitted infections.
Lopman BA, Garnett GP, Mason PR, 
Gregson S (2005) Individual level injection 
history: A lack of association with HIV 
incidence in rural Zimbabwe. DOI: 10.1371/
journal.pmed.0020037
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isolates and uncultured lung tissue samples of SARS-CoV. They 
analyzed isolates taken from 13 patients with SARS at different 
stages of the Singapore outbreak, identiﬁ  ed nine sequence 
variations, and discovered a new primary route of introduction 
of the virus into the Singapore population. They also found a 
Singaporean origin for a German case of SARS, a result that could 
not be derived from standard sequencing methods. The analysis 
of the uncultured lung tissue also found different sequences in 
a single patient, which suggested the presence of multiple viral 
sequence variants in one host. 
The study suggests that MS-based genotyping can be used 
for large-scale genetic characterization of viral DNA from clinical 
samples. The researchers found that the method was accurate 
and sensitive, with a 95% success rat e for detecting sequence 
variations at low virus concentrations. The MS-based assay allows 
high-throughput analysis and complements the “gold standard” 
direct sequence analysis method, which is used to identify 
new sequence variations. As such, it is particularly useful for 
investigating agents for which extensive sequence information 
exists. 
Liu and colleagues propose that the most efﬁ  cient method 
for a large-scale population investigation would be initial 
characterization of a genome sequence by direct sequence 
analysis in a subset of samples, followed by MS-based analysis of 
informative genetic variations. Altogether, their results suggest 
that MS-based genetic analysis can help real-time investigations 
in disease outbreaks.
Liu J, Lim SL, Ruan Y, Ling AE, Ng LFP, et al. (2005) SARS 
transmission pattern in Singapore reassessed by viral sequence 
variation analysis. DOI: 10.1371/journal.pmed.0020043
Antiretroviral drugs change the lives 
of patients with HIV/AIDS—if they have 
access to them. Most patients in resource-
poor countries cannot afford the drugs. 
Major initiatives are under way to expand 
access to antiretrovirals in developing 
countries, but the number of individuals 
in need of the drugs currently vastly 
exceeds the supply, and will continue 
to do so for the foreseeable future. 
These circumstances make for difﬁ  cult 
decisions about treatment allocation. 
David Wilson and Sally Blower have shown 
how it is possible to design an equitable 
antiretroviral allocation strategy, that is, to 
come up with a plan that would give each 
individual with HIV an equal chance of 
receiving antiretrovirals. Their novel spatial 
model enables them to model the “spatial 
diffusion” of antiretrovirals in a resource-
constrained country.
Based on the premise that only a 
limited number of drugs will be available 
and only a limited number of health-care 
facilities can be used for drug distribution 
(each of them serving the population 
in a speciﬁ  c area), they determine an 
optimal equitable allocation strategy. They 
then apply this approach to a practical 
example—the equitable allocation of 
antiretrovirals to patients with HIV/
AIDS in the South African province of 
KwaZulu–Natal. Using data from a detailed 
rollout plan for antiretrovirals designed 
by the South African government, they 
come up with an allocation strategy that 
differs substantially from the current 
governmental plan for the province. 
KwaZulu–Natal has a total of 54 health-
care facilities, of which 17 are assigned 
to allocate antiretrovirals under the 
current plan. It is the largest province in 
South Africa, with a population of about 
9.4 million, and it has more people with 
HIV than any other province (about 21% 
of all cases in South Africa). Wilson and 
Blower assume that the available amount 
of antiretrovirals can treat 10% of the 
individuals with HIV in KwaZulu–Natal. 
Modeling the 17 health-care facilities and 
the 51 communities of individuals with 
HIV, they determine the amount of drugs 
to allocate to each facility to achieve 
equitable access by patients throughout 
the province. They then extend the 
analysis assuming that additional health-
care facilities could be made available 
to distribute drugs. They conclude that 
in order to achieve the greatest degree 
of treatment equality, all 54 health-care 
facilities should be used, and they should, 
on average, each serve the population 
within a radius of 50 km. 
Wilson and Blower discuss how their 
model can be adjusted and therefore used 
by policy makers in resource-constrained 
countries to determine a scientiﬁ  cally 
based allocation strategy for limited 
resources based on a number of speciﬁ  c 
objectives. They also recognize that there 
are other considerations that inﬂ  uence 
ethical treatment allocation besides 
equity, for example, the desire to maximize 
epidemic reduction, or the imperative 
to give priority to the least advantaged 
individuals They believe that their model 
can be adjusted and therefore “used by 
policy makers to determine an optimal 
scientiﬁ  cally based allocation strategy” for 
a number of speciﬁ  c objectives. Another 
possibility would be to apply the equity 
strategy to allocate drugs to particular 
health-care facilities (thereby achieving 
equality in accessibility), and then take 
additional ethical considerations into 
account at the community level. 
Wilson DP, Blower SM (2005) Designing 
equitable antiretroviral allocation strategies 
in resource-constrained countries. DOI: 
10.1371/journal.pmed.0020050
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One of the most common and most 
serious complications of both type 1 and 
type 2 diabetes is diabetic nephropathy. 
It occurs in around 30% of patients 
with type 1 diabetes and 10% to 40% of 
patients with type 2 diabetes. Diabetic 
nephropathy is the leading cause of 
renal failure in the developed world. The 
main effect of diabetic nephropathy is 
proteinuria, initially in very small amounts 
but which increases, leading to nephrotic 
syndrome and end-stage renal disease in 
most cases. 
Various risk factors in individuals 
with diabetes are known to increase 
the chance of developing diabetic 
nephropathy, including South Asian 
or African background, male sex, 
long history of diabetes, poor blood 
sugar control, high blood pressure, 
and smoking. One early change 
associated with diabetic nephropathy 
is degeneration of the renal tubular 
epithelium, but the exact cause of this 
at the cellular level is unclear. Erwin 
Böttinger and colleagues have dissected 
out one key point in the progression 
to diabetic nephropathy. They looked 
at cell lines of renal tubular cells from 
humans and mice and kidney biopsies 
from patients with diabetic nephropathy, 
patients with non-diabetic renal disease, 
and mice with genetic and induced 
diabetes. In the human cell lines they 
showed that glucose induced the 
expression of CD36, a receptor known 
to have a role in adhesion and signal 
transduction (in addition to being 
the receptor for malaria-infected 
erythrocytes). They then went on to show 
that apoptosis of these cells occurred 
in the presence of glycated (glucose-
modiﬁ  ed) albumins or free fatty acids, 
which are present in increased amounts 
in patients with diabetes, and that CD36 
was essential for the apoptosis to occur. 
They then examined how CD36 triggered 
apoptosis and found that it involved src 
kinase, p38 MAP kinase, and caspase 3. 
Comparing mice and humans, the 
researchers found that the two species are 
not alike: diabetic mice did not show an 
increase in tubular expression of CD36—
even though the gene is present in 
mice—and had normal tubular epithelium 
and no tubular apoptosis. They conﬁ  rmed 
this difference between humans and mice 
by showing that normal mouse epithelial 
cell lines were resistant to apoptosis 
caused by the glycated albumins; however, 
artiﬁ  cially expressing CD36 in these lines 
made them susceptible to apoptosis by 
these modiﬁ  ed albumins. 
These results provide insight into one of 
the crucial steps in diabetic nephropathy 
and, in humans at least, might help to 
explain why high blood glucose is so 
damaging to the kidney, hence providing 
a good reason—if another is needed—for 
encouraging patients to control blood 
glucose as tightly as possible. 
Susztak K, Ciccone E, McCue P, Sharma 
K, Böttinger EP (2005) Multiple metabolic 
hits converge on CD36 as novel mediator 
of tubular epithelial apoptosis in diabetic 
nephropathy. DOI: 10.1371/journal.
pmed.0020045
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Pneumonia remains the leading cause of death worldwide in 
children. Several vaccines against pneumococcal pneumonia are 
at various stages of development, but the testing of their efﬁ  cacy 
is hampered by the lack of noninvasive tests that are sensitive 
and speciﬁ  c for the disease. Diagnosis is usually based on chest 
radiographs, which are not very speciﬁ  c for pneumococcal disease. 
In their quest for a more speciﬁ  c diagnostic test, Shabir 
Madhi and colleagues—who are conducting clinical trials 
on pneumococcal vaccines in children—examined whether 
serum concentrations of procalcitonin and C-reactive protein 
could improve the speciﬁ  city of chest radiographs to diagnose 
pneumococcal pneumonia and thus be useful in the future 
evaluation of pneumococcal vaccines. Elevated levels of both 
proteins are associated with bacterial disease. They might 
therefore help to differentiate bacterial from nonbacterial causes 
of pneumonia, and thus allow to “enrich” the analyzed disease 
cases for those of pneumococcal origin, against which the 
vaccine is potentially active. 
This study represents a ﬁ  rst step, in which the researchers 
tested whether adding information about procalcitonin and 
C-reactive protein levels to data from a completed vaccine trial 
would affect the outcome regarding vaccine efﬁ  cacy. When re-
analyzing previous trial data under these conditions, the vaccine 
appeared more efﬁ  cacious compared with placebo when either 
elevated procalcitonin or elevated C-reactive protein levels were 
taken into account. The efﬁ  cacy estimate was greatest when cases 
of pneumonia that had elevated levels of both procalcitonin and 
C-reactive protein were compared against placebo. 
These data suggest that elevated levels of C-reactive protein 
and procalcitonin, in conjunction with chest radiography, 
could improve the speciﬁ  city of a diagnosis of pneumococcal 
pneumonia over that of chest radiography alone. This combined 
diagnostic test could be useful for further evaluation of 
pneumococcal vaccines. The hope is that among patients 
identiﬁ  ed as having pneumonia by the combined test, a higher 
proportion would have pneumonia of pneumococcal origin. As 
a consequence, there would be less “background noise” caused 
by other forms of pneumonia, and this should make it easier 
to assess the efﬁ  cacy of vaccine candidates. However, as the 
researchers point out, this analysis was not a primary objective 
of the present trial. This analysis can therefore serve only as a 
hypothesis-generating study, and as such the hypothesis must 
be tested in other study settings. 
The study was sponsored by Wyeth, manufacturers of the 
pneumococcal vaccine used.
Madhi SA, Heera JR, Kuwanda L, Klugman KP (2005) Use of 
procalcitonin and C-reactive protein to evaluate vaccine efﬁ  cacy 
against pneumonia. DOI: 10.1371/journal.pmed.0020038
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